Sarepta Therapeutics
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| rareDisease | ×0.88 | 4 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| preclinical | ×0.91 | 3 |
Strategy profile
Based on 5 disclosed transactions, Sarepta Therapeutics concentrates its licensing activity in Option Deals, RareDisease, and InfectiousDisease. Sarepta Therapeutics pays a 0.88x discount to market median, with the strongest premiums in RareDisease (0.88x). Their most common deal structure is License, with an average disclosed value of $4.6B. Most recent activity: 2026.
Premium by therapeutic area
How Sarepta Therapeutics pays relative to peer medians in each TA
Pipeline coverage & gaps
Sarepta Therapeutics has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 3 | $708M | $4.0B |
| Collaboration | 2 | $500M | $5.5B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | RNA programs (neurology, pulmonary, musculoskeletal) | Arrowhead Pharmaceuticals | neurology, pulmonary, musculoskeletal | unknown | $500M | $10.0B |
| 2025 | Seven RNA programs (Huntington's disease, DM1, ataxias, pulmonary fibrosis) | Arrowhead | neurology, pulmonary, musculoskeletal | unknown | $500M | $10.0B |
| 2025 | ARO-DM1 | Arrowhead Pharmaceuticals | DMD | unknown | $500M | $825M |
| 2024 | RNA interference program | Arrowhead Pharmaceuticals | — | unknown | — | $1.1B |
| 2024 | neuromuscular | Arrowhead Pharmaceuticals | neuromuscular | preclinical | $1.1B | $1.1B |
How this is computed
For each Sarepta Therapeutics deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 0.879, clamped to [0.7, 1.5].